Skip to content
2000
Volume 23, Issue 46
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Chronic kidney disease (CKD) is associated with dyslipidemia and increased cardiovascular risk. This elevated risk for cardiovascular events exists even in the largest subpopulation with milder stages of CKD, prior to the development of significant reductions in renal excretory function. Statin therapy is a critical component of primary and secondary cardiovascular prevention efforts for at-risk patients. Efficacy in the CKD population, however, has appeared less robust across the spectrum of CKD, particularly in hemodialysis patients. This article will review the current state of knowledge on statin therapy in CKD, effects on renal outcomes, safety in this population and alternative lipid therapies.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/1381612824666180110100103
2017-12-01
2025-05-04
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/1381612824666180110100103
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test